ProfileGDS5678 / 1456383_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 89% 87% 89% 86% 87% 81% 88% 88% 86% 86% 88% 88% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.6765687
GSM967853U87-EV human glioblastoma xenograft - Control 27.0226489
GSM967854U87-EV human glioblastoma xenograft - Control 36.7484387
GSM967855U87-EV human glioblastoma xenograft - Control 47.1313989
GSM967856U87-EV human glioblastoma xenograft - Control 56.4956186
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4286487
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.6477581
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8048788
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.8318688
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5684286
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.5528386
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.862588
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.837888
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5594486